StockData
Arrowhead Pharmaceuticals, Inc. logo

Arrowhead Pharmaceuticals, Inc. (ARWR) shareholders

ARWRNasdaqPharmaceutical PreparationsFiscal year ends September 30
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-K on Nov 12, 2026Score 5/3035% above fair value
$42.99−1.22 (-2.76%)

Close on Nov 17, 2026Market cap $6.07BP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
84.6%
120M of 141M shares
Institutional holders
499
126 new, 58 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 64 sales
Net sold $37.34M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
BlackRock, Inc.14,232,54510.10%13G (passive) amendmentJun 30, 2026
Avoro Capital Advisors LLC
Joint filing with Behzad Aghazadeh (9.64%)
13,823,3839.64%13G (passive) amendmentJun 30, 2026
Sarepta Therapeutics, Inc.
Joint filing with Sarepta Therapeutics Investments, Inc. (9.50%)
11,926,3019.50%13D (active)Feb 7, 2025
Behzad Aghazadeh
Joint filing with Avoro Capital Advisors LLC (8.30%)
11,517,4418.30%13G (passive) amendmentJun 30, 2025
Abigail P. Johnson
Joint filing with FMR LLC (6.60%)
9,307,3506.60%13G (passive) amendmentSep 30, 2026
FMR LLC
Joint filing with Abigail P. Johnson (5.20%)
7,349,1075.20%13G (passive)Mar 31, 2026
Vanguard Capital Management7,081,2935.05%13G (passive)Mar 31, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of ARWRValueChange% of portfolio
BlackRock, Inc.14,830,55310.50%$1.21B−3,330,9660.02%
Avoro Capital Advisors LLC11,355,5558.04%$925.59M+655,5568.31%
FMR LLC8,039,8045.69%$655.32M+773,1520.03%
Vanguard Portfolio Management LLC6,351,3554.50%$517.70M−794,7810.02%
Vanguard Capital Management LLC6,110,9534.33%$498.10M+78,5370.01%
State Street Corp5,694,6404.03%$464.17M−801,4900.01%
Norges Bank3,896,5362.76%$317.61MNew0.03%
Invesco Ltd.3,883,9762.75%$316.58M+603,3290.03%
Geode Capital Management, LLC3,530,6122.50%$298.81M−748,2160.02%
Fred Alger Management, LLC3,301,9192.34%$269.14M−40,5740.90%
Baker Bros. Advisors LP1,992,7831.41%$162.43M–0.81%
Siren, L.L.C.1,715,4761.21%$139.83M+100,0002.83%
Vestal Point Capital, LP1,575,0001.12%$128.38M−700,0003.00%
Deerfield Management Company, L.P. (Series C)1,389,0550.98%$113.22M−184,2421.18%
First Trust Advisors LP1,352,9180.96%$110.28M+1,203,7700.06%
Driehaus Capital Management LLC1,350,5560.96%$110.08M+160,2210.64%
Jupiter Topco LLC1,221,5960.86%$99.62MNew0.04%
Northern Trust Corp1,192,8680.84%$97.23M−462,9690.01%
Dimensional Fund Advisors LP1,181,6080.84%$96.31M+573,0770.02%
Goldman Sachs Group Inc1,150,0070.81%$93.74M−589,9160.01%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026499120M84.6%126 / 153157 / 5818M18M
Q1 2026437121M85.5%106 / 171112 / 6236M16M
Q4 2025401116M82.1%127 / 125110 / 2717M13M
Q3 2025303112M79.1%66 / 10182 / 4117M11M
Q2 2025281106M75.2%57 / 9782 / 3813M12M
Q1 2025264105M74.5%43 / 8981 / 4717M11M
Q4 2024270100M70.6%44 / 9385 / 429M10M
Q3 2024272100M70.8%34 / 9290 / 3226M11M
Q2 2024272100M70.8%34 / 9787 / 349M9M
Q1 2024273102M72.0%40 / 10775 / 3029M9M
Q4 202326681M57.5%44 / 7796 / 3413M7M
Q3 202325675M53.0%21 / 9196 / 387M5M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

469 funds held ARWR in Q2 2026, 59% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of ARWRValue% of fundAs of
iShares Core S&P Mid-Cap ETF4,820,4743.41%$392.92M0.32%Jun 30, 2026
Vanguard Total Stock Market Index Fund4,246,6373.01%$346.14M0.02%Jun 30, 2026
Vanguard Small-Cap Index Fund3,067,8192.17%$250.06M0.13%Jun 30, 2026
Fidelity Growth Company Fund2,362,3711.67%$184.05M0.19%May 31, 2026
Vanguard Small-Cap Growth Index Fund1,768,6351.25%$144.16M0.31%Jun 30, 2026
Invesco S&P MidCap Momentum ETF1,736,4751.23%$146.99M2.05%Jul 31, 2026
Vanguard Extended Market Index Fund1,614,9241.14%$131.63M0.13%Jun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF1,407,5871.00%$114.73M1.07%Jun 30, 2026
First Trust NYSE Arca Biotechnology Index Fund1,165,1270.82%$94.97M3.38%Jun 30, 2026
iShares Biotechnology ETF937,6990.66%$76.43M0.84%Jun 30, 2026
iShares S&P Mid-Cap 400 Growth ETF842,6870.60%$68.69M0.61%Jun 30, 2026
Alger Focus Equity Fund762,5140.54%$64.55M0.91%Jul 31, 2026
Fidelity Extended Market Index Fund720,8890.51%$56.16M0.13%May 31, 2026
State Street(R) SPDR(R) Portfolio S&P 400(TM) Mid Cap ETF712,9850.50%$58.12M0.32%Jun 30, 2026
Vanguard Russell 2000 Index Fund694,9900.49%$54.15M0.31%May 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Christopher Richard AnzaloneChief Executive Officer, Director3,798,5102.69%Jan 5, 2026
Daniel Joseph ApelChief Financial Officer172,7920.12%Apr 24, 2026
James C. HamiltonChief Medical Officer226,9580.16%Apr 24, 2026
Patrick O'BrienCOO472,8480.33%Jan 8, 2026
Kenneth Allen MyszkowskiChief Financial Officer465,4330.33%Jan 7, 2025
Adeoye Y. OlukotunDirector31,6000.02%Aug 20, 2026
Michael S. PerryDirector111,4590.08%Aug 20, 2026
Matthew Gregory CohenDirector11,8820.01%Jun 17, 2026
Hongbo LuDirector57,6620.04%May 14, 2026
Mauro FerrariDirector69,0530.05%Dec 30, 2025
William D. WaddillDirector56,5630.04%Dec 23, 2025
Victoria VakienerDirector37,6830.03%Dec 23, 2025
Douglas S. IngramDirector46,2150.03%Dec 18, 2025
Douglas B. GivenDirector136,6670.10%Dec 18, 2024

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Michael S. Perry
Director
Aug 18, 2026Sale−11,600$87.30$1.01M111,459
Adeoye Y. Olukotun
Director
Aug 18, 2026Sale−2,000$86.96$173.92K31,600
Matthew Gregory Cohen
Director
Jun 15, 2026Award+11,882––11,882
Hongbo Lu
Director
May 12, 2026Sale(10b5-1 plan)−2,970$76.88$228.33K52,012
James C. Hamilton
Chief Medical Officer
Apr 23, 2026Sale(10b5-1 plan)−10,000$75.00$750.00K226,958
Daniel Joseph Apel
Chief Financial Officer
Apr 22, 2026Sale(10b5-1 plan)−3,208$70.11$224.91K172,792
Daniel Joseph Apel
Chief Financial Officer
Apr 22, 2026Sale(10b5-1 plan)−1,157$70.45$81.51K171,635
Daniel Joseph Apel
Chief Financial Officer
Apr 22, 2026Sale(10b5-1 plan)−8,730$71.92$627.86K162,905
James C. Hamilton
Chief Medical Officer
Mar 5, 2026Sale(10b5-1 plan)−10,000$64.19$641.90K236,958
Patrick O'Brien
COO
Jan 6, 2026Gift−440––472,848
Patrick O'Brien
COO
Jan 6, 2026Gift−540––474,368
Patrick O'Brien
COO
Jan 6, 2026Gift−540––473,828
Patrick O'Brien
COO
Jan 6, 2026Gift−440––472,408
Patrick O'Brien
COO
Jan 6, 2026Award+75,000––547,408
Patrick O'Brien
COO
Jan 6, 2026Gift−540––473,288
Daniel Joseph Apel
Chief Financial Officer
Jan 6, 2026Award+75,000––176,200
James C. Hamilton
Chief Medical Officer
Jan 6, 2026Award+75,000––246,958
James C. Hamilton
Chief Medical Officer
Jan 5, 2026Sale(10b5-1 plan)−12,711$63.95$812.87K173,904
James C. Hamilton
Chief Medical Officer
Jan 5, 2026Sale(10b5-1 plan)−437$65.97$28.83K172,267
James C. Hamilton
Chief Medical Officer
Jan 5, 2026Sale(10b5-1 plan)−1,200$64.49$77.39K172,704
James C. Hamilton
Chief Medical Officer
Jan 5, 2026Sale(10b5-1 plan)−309$68.00$21.01K171,958
James C. Hamilton
Chief Medical Officer
Jan 5, 2026Sale(10b5-1 plan)−14,792$63.01$932.04K186,615
James C. Hamilton
Chief Medical Officer
Jan 5, 2026Sale(10b5-1 plan)−6,090$62.28$379.29K201,407
James C. Hamilton
Chief Medical Officer
Jan 5, 2026Sale(10b5-1 plan)−4,625$61.24$283.24K207,497
Patrick O'Brien
COO
Jan 5, 2026Sale(10b5-1 plan)−2,336$64.04$149.60K474,954
Patrick O'Brien
COO
Jan 5, 2026Sale(10b5-1 plan)−5,873$62.91$369.47K477,290
Patrick O'Brien
COO
Jan 5, 2026Sale(10b5-1 plan)−900$62.25$56.03K483,163
Patrick O'Brien
COO
Jan 5, 2026Sale(10b5-1 plan)−600$61.12$36.67K484,063
Patrick O'Brien
COO
Jan 5, 2026Sale(10b5-1 plan)−313$68.00$21.28K484,663
Patrick O'Brien
COO
Jan 5, 2026Sale(10b5-1 plan)−900$66.01$59.41K484,976
Patrick O'Brien
COO
Jan 5, 2026Sale(10b5-1 plan)−2,700$64.44$173.99K485,876
Patrick O'Brien
COO
Jan 5, 2026Sale(10b5-1 plan)−11,842$63.84$755.99K488,576
Patrick O'Brien
COO
Jan 5, 2026Sale(10b5-1 plan)−13,451$62.96$846.87K500,418
Patrick O'Brien
COO
Jan 5, 2026Sale(10b5-1 plan)−6,164$62.23$383.59K513,869
Patrick O'Brien
COO
Jan 5, 2026Sale(10b5-1 plan)−4,368$61.20$267.32K520,033
Patrick O'Brien
COO
Jan 5, 2026Sale(10b5-1 plan)−46$68.00$3.13K474,908
Christopher Richard Anzalone
Chief Executive Officer, Director
Jan 2, 2026Sale(10b5-1 plan)−7,416$65.88$488.57K3,798,510
Christopher Richard Anzalone
Chief Executive Officer, Director
Jan 2, 2026Sale(10b5-1 plan)−5,771$66.39$383.14K3,792,739
Patrick O'Brien
COO
Dec 31, 2025Gift−560––526,081
Patrick O'Brien
COO
Dec 31, 2025Gift−560––524,401
Patrick O'Brien
COO
Dec 31, 2025Gift−560––524,961
Patrick O'Brien
COO
Dec 31, 2025Gift−560––525,521
Patrick O'Brien
COO
Dec 31, 2025Gift−560––526,641
Christopher Richard Anzalone
Chief Executive Officer, Director
Dec 29, 2025Option exercise+35,181$6.15$216.36K3,841,107
Christopher Richard Anzalone
Chief Executive Officer, Director
Dec 29, 2025Option exercise+16,545$6.15$101.75K3,857,652
Christopher Richard Anzalone
Chief Executive Officer, Director
Dec 29, 2025Sale(10b5-1 plan)−35,181$69.33$2.44M3,822,471
Christopher Richard Anzalone
Chief Executive Officer, Director
Dec 29, 2025Sale(10b5-1 plan)−16,545$68.69$1.14M3,805,926
Mauro Ferrari
Director
Dec 26, 2025Sale(10b5-1 plan)−7,530$70.00$527.10K69,053
Christopher Richard Anzalone
Chief Executive Officer, Director
Dec 22, 2025Sale(10b5-1 plan)−10,012$68.33$684.12K3,808,500
Christopher Richard Anzalone
Chief Executive Officer, Director
Dec 22, 2025Sale(10b5-1 plan)−2,574$68.85$177.22K3,805,926
Adeoye Y. Olukotun
Director
Dec 19, 2025Sale(10b5-1 plan)−827$68.48$56.63K33,600
Adeoye Y. Olukotun
Director
Dec 19, 2025Sale(10b5-1 plan)−6,083$68.04$413.89K34,427
Adeoye Y. Olukotun
Director
Dec 19, 2025Sale(10b5-1 plan)−3,090$66.70$206.10K40,510
William D. Waddill
Director
Dec 19, 2025Sale(10b5-1 plan)−500$68.53$34.27K56,563
William D. Waddill
Director
Dec 19, 2025Sale(10b5-1 plan)−2,416$66.66$161.05K62,514
William D. Waddill
Director
Dec 19, 2025Sale(10b5-1 plan)−5,451$68.01$370.72K57,063
Christopher Richard Anzalone
Chief Executive Officer, Director
Dec 19, 2025Sale(10b5-1 plan)−1,319$68.48$90.33K3,818,512
Christopher Richard Anzalone
Chief Executive Officer, Director
Dec 19, 2025Sale(10b5-1 plan)−8,147$68.01$554.08K3,819,831
Christopher Richard Anzalone
Chief Executive Officer, Director
Dec 19, 2025Sale(10b5-1 plan)−3,979$66.67$265.28K3,827,978
Victoria Vakiener
Director
Dec 19, 2025Sale(10b5-1 plan)−5,281$67.97$358.95K37,683

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
8.54%
12M shares short
Days to cover
8.5
At 1M shares a day
Change since last report
+5.7%
From 11M shares
Short volume, 20 days
50.7%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Arrowhead Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 8,174 shares on Sep 28, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Michael S. Perry
Director
Aug 18, 202611,600$1.01MAug 18, 2026Compensation
Adeoye Y. Olukotun
Director
Aug 18, 20262,000$173.88KAug 18, 2026Compensation
Daniel Joseph Apel
Officer
May 19, 202613,095$934.21KApr 22, 2026Bonus
Hongbo Lu
Officer
May 19, 20262,970$228.30KMay 12, 2026Compensation
James C. Hamilton
Officer
May 19, 202610,000$750.00KApr 23, 2026Compensation
Hongbo Lu
Officer
May 12, 20262,970$228.30KMay 12, 2026Compensation
James C. Hamilton
Officer
Apr 23, 202610,000$750.00KApr 23, 2026Compensation
Daniel Joseph Apel
Officer
Apr 22, 202613,095$934.21KApr 22, 2026Bonus
James C. Hamilton
Officer
Mar 5, 202610,000$641.87KMar 5, 2026Compensation
Patrick O'Brien
Officer
Jan 5, 202649,493$3.12MJan 5, 2026Compensation
James C. Hamilton
Officer
Jan 5, 202639,728$2.51MJan 5, 2026Compensation
James C. Hamilton
Officer
Jan 5, 202640,164$2.53MJan 5, 2026Compensation
Christopher Richard Anzalone
Officer
Jan 2, 202613,187$871.67KJan 2, 2026Compensation
Christopher Richard Anzalone
Officer
Dec 29, 202551,726$3.58MDec 29, 2025Compensation
Mauro Ferrari
Director
Dec 29, 20257,530$527.07KDec 26, 2025Compensation

Congress trades

1 trade in Arrowhead Pharmaceuticals reported by 1 member of the House

MemberTypeTradedAmountFiled
Daniel Goldman
NY10
SoldJan 31, 2023$1K–15KFeb 24, 2023

See a number that looks wrong?